NYSEMKT:PHGE BiomX (PHGE) Stock Forecast, Price & News $0.33 -0.01 (-2.94%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.33▼$0.3650-Day Range$0.32▼$0.4352-Week Range N/AVolume12,810 shsAverage Volume28,619 shsMarket Capitalization$15.17 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media BiomX MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,263.6% Upside$4.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.44) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, BiomX has a forecasted upside of 1,263.6% from its current price of $0.33.Amount of Analyst CoverageBiomX has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PHGE. Previous Next 0.0 Dividend Strength Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHGE. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for PHGE on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.21% of the stock of BiomX is held by insiders.Percentage Held by InstitutionsOnly 36.67% of the stock of BiomX is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BiomX are expected to grow in the coming year, from ($0.44) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BiomX (NYSEMKT:PHGE) StockBiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Read More PHGE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHGE Stock News HeadlinesAugust 9, 2023 | msn.comHC Wainwright & Co. Reiterates BiomX (PHGE) Buy RecommendationAugust 9, 2023 | msn.comBiomX GAAP EPS of -$0.12 beats by $0.02September 30, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.July 19, 2023 | uk.finance.yahoo.comPHGE - BiomX Inc.June 2, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings with Respect to the Warrants of BiomX Inc. (PHGE.WS)May 31, 2023 | finance.yahoo.comBiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)May 16, 2023 | msn.comHC Wainwright & Co. Maintains BiomX (PHGE) Buy RecommendationMay 12, 2023 | finance.yahoo.comBiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of DirectorsSeptember 30, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 12, 2023 | msn.comWhy Is BiomX (PHGE) Stock Up 10% Today?May 8, 2023 | finance.yahoo.comBiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023April 27, 2023 | ca.finance.yahoo.comBiomX Inc. (PHGE) Stock Historical Prices & Data - Yahoo FinanceApril 19, 2023 | ca.finance.yahoo.comBiomX Inc. (PHGE-WT)April 9, 2023 | finance.yahoo.comBiomX Inc. (AMEX:PHGE) Q4 2022 Earnings Call TranscriptApril 1, 2023 | benzinga.comBiomX Stock (AMEX:PHGE), DividendsMarch 29, 2023 | finance.yahoo.comBiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateFebruary 22, 2023 | finance.yahoo.comBiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic FibrosisFebruary 22, 2023 | finance.yahoo.comBiomX Announces $7.5 Million Private PlacementNovember 1, 2022 | msn.comWall Street Set to Open Higher Ahead of Manufacturing PMI, Fed MeetingOctober 5, 2022 | theglobeandmail.comBiomX: Top 10 Undervalued Healthcare Stocks on ASE (PHGE)September 1, 2022 | investing.comPHGE_u Technical AnalysisAugust 11, 2022 | seekingalpha.comBiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2022 Results - Earnings Call TranscriptAugust 7, 2022 | finance.yahoo.comBiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022June 28, 2022 | seekingalpha.comBiomX stock rises on team up with Boehringer inflammatory bowel disease biomarkersMay 11, 2022 | seekingalpha.comBiomX Inc. (PHGE) CEO Jonathan Solomon on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | finance.yahoo.comBiomX Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 5, 2022 | finance.yahoo.comBiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022See More Headlines Receive PHGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter. Email Address PHGE Company Calendar Last Earnings5/15/2023Today9/29/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSEMKT:PHGE CUSIPN/A CIK1739174 Webwww.biomx.com Phone972 7 23942377FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+1,263.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-127.82% Return on Assets-56.50% Debt Debt-to-Equity Ratio0.51 Current Ratio2.84 Quick Ratio2.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book0.47Miscellaneous Outstanding Shares45,980,000Free Float44,044,000Market Cap$15.17 million OptionableNot Optionable Beta1.31 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Jonathan Eitan Solomon MBA (Age 46)CEO & Director Comp: $528.57kMs. Marina Wolfson CPA (Age 39)CFO & Sec. Comp: $279.42kDr. Merav Bassan Ph.D. (Age 57)Chief Devel. Officer Comp: $356.59kProf. Rotem Sorek Ph.D.Scientific FounderDr. Eran Elinav M.D.Ph.D., Scientific FounderDr. Timothy K. Lu M.D. (Age 42)Ph.D., Scientific Founder Ms. Inbal Benjamini-ElranC.H.R.OMr. Assaf Oron (Age 49)Chief Bus. Officer Dr. Inbar Gahali-SassVP of Platform R&DMore ExecutivesKey CompetitorsHarpoon TherapeuticsNASDAQ:HARPFreeline TherapeuticsNASDAQ:FRLNMicrobot MedicalNASDAQ:MBOTGenetic TechnologiesNASDAQ:GENEBrainstorm Cell TherapeuticsNASDAQ:BCLIView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 117,195 shares on 8/11/2023Ownership: 0.589%Assaf OronBought 3,192 shares on 5/22/2023Total: $861.84 ($0.27/share)Israel Biofund Gp Limi OrbimedBought 348,000 shares on 2/27/2023Total: $83,520.00 ($0.24/share)Chidozie UgwumbaSold 1,501 sharesTotal: $570.38 ($0.38/share)Chidozie UgwumbaSold 2,416 sharesTotal: $869.76 ($0.36/share)View All Insider TransactionsView All Institutional Transactions PHGE Stock - Frequently Asked Questions Should I buy or sell BiomX stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BiomX in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHGE shares. View PHGE analyst ratings or view top-rated stocks. What is BiomX's stock price forecast for 2023? 3 brokers have issued 12-month price objectives for BiomX's shares. Their PHGE share price forecasts range from $2.00 to $7.00. On average, they predict the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 1,263.6% from the stock's current price. View analysts price targets for PHGE or view top-rated stocks among Wall Street analysts. How have PHGE shares performed in 2023? BiomX's stock was trading at $0.1870 at the beginning of 2023. Since then, PHGE stock has increased by 76.5% and is now trading at $0.33. View the best growth stocks for 2023 here. When is BiomX's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our PHGE earnings forecast. How were BiomX's earnings last quarter? BiomX Inc. (NYSEMKT:PHGE) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.02. What other stocks do shareholders of BiomX own? Based on aggregate information from My MarketBeat watchlists, some companies that other BiomX investors own include Abiomed (ABMD), Catalent (CTLT), Hologic (HOLX), Merck & Co., Inc. (MRK), Net Element (NETE), Novavax (NVAX), Quanterix (QTRX), ARCA biopharma (ABIO), AbbVie (ABBV) and AudioEye (AEYE). What is BiomX's stock symbol? BiomX trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PHGE." How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BiomX's stock price today? One share of PHGE stock can currently be purchased for approximately $0.33. How much money does BiomX make? BiomX (NYSEMKT:PHGE) has a market capitalization of $15.17 million. The company earns $-28,320,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. How can I contact BiomX? BiomX's mailing address is 7 PINHAS SAPIR ST. FLOOR 2, NESS ZIONA L3, 7414002. The official website for the company is www.biomx.com. The company can be reached via phone at 972 7 23942377 or via email at noelk@biomx.com. This page (NYSEMKT:PHGE) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.